Showing 1 - 9 results of 9 for search 'Accountancy', query time: 0.17s Refine Results
  1. 1
    Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
    by N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov
    Published 2019-01-01
    “... share of direct medical treatment costs, are automatically accounted for 84 Russian regions (except...”
    Get full text
    Article
  2. 2
    Pharmacoeconomic analysis of leuprolide acetate (Eligard) 45 mg once in 6 months for advanced prostate cancer in Russian Federation
    by M. Yu. Frolov, M. V. Avksentyeva
    Published 2015-12-01
    “... into account 5 year survival rate. One-way sensitivity analysis was performed.Results. Leuprolide acetate...”
    Get full text
    Article
  3. 3
    Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm
    by M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov
    Published 2021-02-01
    “...). The direct medical costs of providing care for COVID-19 were taken into account (ICU service, the cost...”
    Get full text
    Article
  4. 4
    DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY
    “... on dispensed medicines from 42 regions of the Russian Federation, which accounted for 57.58% of the total...”
    Get full text
    Article
  5. 5
    Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
    “.... Only cost of drugs was taken into account. Adalimumab (ADA) and infliximab (INF) were used...”
    Get full text
    Article
  6. 6
    Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
    by N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov
    Published 2020-02-01
    “... medications and adverse event treatments were considered. We accounted for treatment discontinuation and CDK4...”
    Get full text
    Article
  7. 7
    CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS
    “... system have been calculated taking into account the management peculiarities and financing of medical...”
    Get full text
    Article
  8. 8
    PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
    “...Background. Breast cancer is the most common malignant tumor and accounts for the most number...”
    Get full text
    Article
  9. 9
    CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY
    by E. A. Pyadushkina, M. Yu. Frolov
    Published 2016-12-01
    “..., for the account of healthcare and social security budget of the constituent members of the Russian Federation; 2...”
    Get full text
    Article
Search Tools: Get RSS Feed — Email this Search